285 related articles for article (PubMed ID: 27799738)
1. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Dörr J; Baum K
Drug Des Devel Ther; 2016; 10():3379-3386. PubMed ID: 27799738
[TBL] [Abstract][Full Text] [Related]
2. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
4. ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Ruck T; Afzali AM; Lukat KF; Eveslage M; Gross CC; Pfeuffer S; Bittner S; Klotz L; Melzer N; Wiendl H; Meuth SG
BMC Neurol; 2016 Mar; 16():34. PubMed ID: 26966029
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
6. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
7. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of alemtuzumab for multiple sclerosis.
Willis M; Robertson NP
Expert Opin Drug Saf; 2014 Aug; 13(8):1115-24. PubMed ID: 24935240
[TBL] [Abstract][Full Text] [Related]
9. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
10. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
12. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
[TBL] [Abstract][Full Text] [Related]
13. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab in multiple sclerosis: an update.
Gross RH; Krieger S
Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
[TBL] [Abstract][Full Text] [Related]
16. [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].
Klotz L; Meuth SG; Kieseier B; Wiendl H
Nervenarzt; 2013 Aug; 84(8):984-94. PubMed ID: 23793409
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
18. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
Illés Z; Sejbaek T; Csépány T
Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
[TBL] [Abstract][Full Text] [Related]
19. [Alemtuzumab: a further option for treatment of multiple sclerosis].
Menge T; Kieseier BC; Warnke C; Aktas O; Hartung HP
Nervenarzt; 2012 Apr; 83(4):487-501. PubMed ID: 22038387
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
